Exicure, Inc. (NASDAQ:XCUR) Major Shareholder Acquires $711,669.00 in Stock

Exicure, Inc. (NASDAQ:XCUR) major shareholder Co. Ltd. Dgp acquired 237,223 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was bought at an average cost of $3.00 per share, with a total value of $711,669.00. Following the purchase, the insider now owns 849,223 shares in the company, valued at $2,547,669. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Exicure Trading Up 41.3 %

NASDAQ:XCUR traded up $0.66 on Monday, hitting $2.26. The company had a trading volume of 18,970,292 shares, compared to its average volume of 377,786. The stock has a market capitalization of $19.55 million, a price-to-earnings ratio of -1.49 and a beta of 1.24. The firm has a 50 day moving average of $0.53 and a two-hundred day moving average of $0.25. Exicure, Inc. has a 52 week low of $1.44 and a 52 week high of $4.75.

Exicure (NASDAQ:XCUR) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.01) EPS for the quarter.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.